Adeno-associated virus-mediated anti-DR5 chimeric antibody expression suppresses human tumor growth in nude mice

Cancer Letters

Volumn 302, Issue 2, 2011, Pages 119-127

  Lv, Fujia ^a   Qiu, Yuhe ^a   Zhang, Yaxi ^a   Liu, Shilian ^a   Shi, Juan ^a   Liu, Yanxin ^a   Zheng, Dexian ^a  

^a INSTITUTE OF BASIC MEDICAL SCIENCES   (China)

Author keywords

Cancer therapy; Chimeric antibody; Death receptor 5; Gene transfer

Indexed keywords

ANTINEOPLASTIC AGENT; CHIMERIC ANTIBODY; DEATH RECEPTOR 5 ANTIBODY; PARVOVIRUS VECTOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BINDING AFFINITY; CANCER CELL; CANCER GENE THERAPY; CANCER INHIBITION; COLON CANCER; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG MEGADOSE; DRUG RECEPTOR BINDING; GENE EXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LIVER CANCER; LOW DRUG DOSE; MALE; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; TUMOR; TUMOR XENOGRAFT; VIRAL GENE DELIVERY SYSTEM; VIRUS PARTICLE; VIRUS RECOMBINANT;

ANIMALS; ANTIBODIES, MONOCLONAL; APOPTOSIS; BLOTTING, WESTERN; CELL LINE, TUMOR; DEPENDOVIRUS; GENE EXPRESSION REGULATION; GENE THERAPY; HUMANS; IMMUNOTHERAPY; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASMS; RECEPTORS, TNF-RELATED APOPTOSIS-INDUCING LIGAND; RECOMBINANT PROTEINS;

ADENO-ASSOCIATED VIRUS; MUS MUSCULUS;

EID: 79951581625     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2011.01.001     Document Type: Article

References (35)

1. Wiley S.R., Schooley K., Smolak P.J., Din W.S., Huang C.P., Nicholl J.K., et al. Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 1995, 3:673-682.
2. Pan G., O'Rourke K., Chinnaiyan A.M., Gentz R., Ebner R., Ni J., et al. The receptor for the cytotoxic ligand TRAIL. Science 1997, 276:111-113.
3. Walczak H., Degli-Esposti M.A., Johnson R.S., Smolak P.J., Waugh J.Y., Boiani N., et al. TRAIL-R2: a novel apoptosis-mediating receptor for TRAIL. EMBO J. 1997, 16:5386-5397.
4. Chaudhary P.M., Eby M., Jasmin A., Bookwalter A., Murray J., Hood L. Death receptor 5, a new member of the TNFR family, and DR4 induce FADD-dependent apoptosis and activate the NF-kappaB pathway. Immunity 1997, 7:821-830.
5. Marsters S.A., Sheridan J.P., Pitti R.M., Huang A., Skubatch M., Baldwin D., et al. A novel receptor for Apo2L/TRAIL contains a truncated death domain. Curr. Biol. 1997, 7:1003-1006.
6. Degli-Esposti M.A., Smolak P.J., Walczak H., Waugh J., Huang C.P., DuBose R.F., et al. Cloning and characterization of TRAIL-R3, a novel member of the emerging TRAIL receptor family. J. Exp. Med. 1997, 186:1165-1170.
7. Emery J.G., McDonnell P., Burke M.B., Deen K.C., Lyn S., Silverman C., et al. Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL. J. Biol. Chem. 1998, 273:14363-14367.
8. Walczak H., Haas T.L. Biochemical analysis of the native TRAIL death-inducing signaling complex. Methods Mol. Biol. 2008, 414:221-239.
9. Thorburn A. Death receptor-induced cell killing. Cell. Signal. 2004, 16:139-144.
10. Korsmeyer S.J., Wei M.C., Saito M., Weiler S., Oh K.J., Schlesinger P.H. Pro-apoptotic cascade activates BID, which oligomerizes BAK or BAX into pores that result in the release of cytochrome c. Cell Death Differ. 2000, 7:1166-1173.
11. Daniels R.A., Turley H., Kimberley F.C., Liu X.S., Mongkolsapaya J., Ch'En P., et al. Expression of TRAIL and TRAIL receptors in normal and malignant tissues. Cell Res. 2005, 15:430-438.
12. Grosse-Wilde A., Voloshanenko O., Bailey S.L., Longton G.M., Schaefer U., Csernok A.I., et al. TRAIL-R deficiency in mice enhances lymph node metastasis without affecting primary tumor development. J. Clin. Invest. 2008, 118:100-110.
13. Herbeuvala J.P., Shearer G.M. HIV-1 immunopathogenesis: how good interferon turns bad. Clin. Immunol. 2007, 123:121-128.
14. Ishikawa E., Nakazawa M., Yoshinari M., Minami M. Role of tumor necrosis factor-related apoptosis-inducing ligand in immune response to influenza virus infection in mice. J. Virol. 2005, 79:7658-7663.
15. Griffith T.S., Wiley S.R., Kubin M.Z., Sedger L.M., Maliszewski C.R., Fanger N.A. Monocyte-mediated tumoricidal activity via the tumor necrosis factor-related cytokine, TRAIL. J. Exp. Med. 1999, 189:1343-1354.
16. Jo M., Kim T.H., Seol D.W., Esplen J.E., Dorko K., Billiar T.R., et al. Apoptosis induced in normal human hepatocytes by tumor necrosis factor-related apoptosis-inducing ligand. Nat. Med. 2000, 6:564-567.
17. Qin J.Z., Bacon P.E., Chaturvedi V., Bonish B., Nickoloff B.J. Pathways involved in proliferating, senescent and immortalized keratinocyte cell death mediated by two different TRAIL preparations. Exp. Dermatol. 2002, 11:573-583.
18. Renshaw S.A., Parmar J.S., Singleton V., Rowe S.J., Dockrell D.H., Dower S.K., et al. Acceleration of human neutrophil apoptosis by TRAIL. J. Immunol. 2003, 170:1027-1033.
19. Lawrence D., Shahrokh Z., Marsters S., Achilles K., Shih D., Mounho B., et al. Differential hepatocyte toxicity of recombinant Apo2L/TRAIL versions. Nat. Med. 2001, 7:383-385.
20. Zhang L., Zhang X., Barrisford G.W., Olumi A.F. Lexatumumab (TRAIL-receptor 2 mAb) induces expression of DR5 and promotes apoptosis in primary and metastatic renal cell carcinoma in a mouse orthotopic model. Cancer Lett. 2007, 251:146-157.
21. Oliver P.G., LoBuglio A.F., Zinn K.R., Kim H., Nan L., Zhou T., et al. Treatment of human colon cancer xenografts with TRA-8 anti-death receptor 5 antibody alone or in combination with CPT-11. Clin. Cancer Res. 2008, 14:2180-2189.
22. Frederick P.J., Kendrick J.E., Straughn Jr J.M., Della Manna D.L., Oliver P.G., Lin H.Y., et al. Effect of TRA-8 anti-death receptor 5 antibody in combination with chemotherapy in an ex vivo human ovarian cancer model. Int. J. Gynecol. Cancer 2009, 19:814-819.
23. Luster T.A., Carrell J.A., McCormick K., Sun D., Humphreys R. Mapatumumab and lexatumumab induce apoptosis in TRAIL-R1 and TRAIL-R2 antibody-resistant NSCLC cell lines when treated in combination with bortezomib. Mol. Cancer Ther. 2009, 8:292-302.
24. Smith M.R., Jin F., Joshi I. Bortezomib sensitizes non-Hodgkin's lymphoma cells to apoptosis induced by antibodies to tumor necrosis factor related apoptosis-inducing ligand (TRAIL) receptors TRAIL-R1 and TRAIL-R2. Clin. Cancer Res. 2007, 13:5528s-5534s.
25. Scott A.M., Liu Z., Murone C., Johns T.G., MacGregor D., Smyth F.E., et al. Immunological effects of chimeric anti-GD3 monoclonal antibody KM871 in patients with metastatic melanoma. Cancer Immun. 2005, 5:3-15.
26. Ghetie V., Ward E.S. FcRn: the MHC class I-related receptor that is more than an IgG transporter. Immunol. Today 1997, 18:592-598.
27. Grimm D., Lee J.S., Wang L., Desai T., Akache B., Storm T.A., et al. In vitro and in vivo gene therapy vector evolution via multispecies interbreeding and retargeting of adeno-associated viruses. J. Virol. 2008, 82:5887-5911.
28. Guo Y., Chen C., Zheng Y., Zhang J., Tao X., Liu S., et al. A novel anti-human DR5 monoclonal antibody with tumoricidal activity induces caspase-dependent and caspase-independent cell death. J. Biol. Chem. 2005, 280:41940-41952.
29. Yamashita M., Katakura Y., Shirahata S. Recent advances in the generation of human monoclonal antibody. Cytotechnology 2007, 55:55-60.
30. Shi J., Liu Y., Zheng Y., Guo Y., Zhang J., Cheung P.T., et al. Therapeutic expression of an anti-death receptor 5 single-chain fixed-variable region prevents tumor growth in mice. Cancer Res. 2006, 66:11946-11953.
31. Zhang Y., Ma H., Zhang J., Liu S., Liu Y., Zheng D. AAV-mediated TRAIL gene expression driven by hTERT promoter suppressed human hepatocellular carcinoma growth in mice. Life Sci. 2008, 82:1154-1161.
32. Sánchez-Mejorada G., Rosales C. Signal transduction by immunoglobulin Fc receptors. J. Leukoc. Biol. 1998, 63:521-533.
33. Nechansky A., Szolar O.H., Siegl P., Zinoecker I., Halanek N., Wiederkum S., et al. Complement dependent cytotoxicity (CDC) activity of a humanized anti Lewis-Y antibody: FACS-based assay versus the 'classical' radioactive method - qualification, comparison and application of the FACS-based approach. J. Pharm. Biomed. Anal. 2009, 49:1014-1020.
34. Keizer R.J., Huitema A.D., Schellens J.H., Beijnen J.H. Clinical pharmacokinetics of therapeutic monoclonal antibodies. Clin. Pharmacokinet. 2010, 49:493-507.
35. Baert F., Noman M., Vermeire S., Van Assche G., D' Haens G., Carbonez A., et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N. Engl. J. Med. 2003, 348:601-608.